Trial Profile
Effects of 6 Weeks Treatment With a Dipeptidyl Peptidase 4 Inhibitor on Counterregulatory and Incretin Hormones During Acute Hypoglycaemia in Patients With Type 1 Diabetes: a Randomized Double Blind Placebo-controlled Cross-over Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DARE
- 27 Sep 2013 Primary endpoint 'Glucagon-levels' has not been met.
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 11 Aug 2013 Status changed from active, no longer recruiting to completed.